Masimo shares drop as Q4 revenue guidance disappoints

IRVINE, California - Masimo (NASDAQ:MASI ) Corporation (NASDAQ:MASI ) reported third-quarter earnings that beat analyst expectations, but its shares tumbled 7.5% as fourth-quarter revenue guidance fell short of estimates.

The medical technology company posted adjusted earnings per share of $0.98 for the third quarter, surpassing the analyst consensus of $0.84. Revenue came in at $504.6 million, slightly above the $502.87 million estimate and up 11.5% YoY.

However, Masimo's fourth-quarter revenue guidance of $581-611 million fell below the $607.5 million analyst consensus at the midpoint. The company expects fourth-quarter EPS between $1.35 and $1.50, compared to the $1.41 consensus.

For the full year 2024, Masimo raised its EPS guidance to $3.95-$4.10, above the $3.88 consensus. Full-year revenue is projected at $2.075-2.105 billion, in line with the $2.1 billion estimate.

Michelle Brennan, Interim CEO, commented on the results: "We are pleased to report strong third quarter performance, driven by our core healthcare segment. We appreciate the commitment and energy of our employees, which has resulted in a seamless transition since our Annual Meeting with no disruption to our business or departures of critical talent."

The company shipped 60,500 noninvasive technology boards and instruments during the quarter. Healthcare revenue, which makes up the bulk of Masimo's business, grew 11.7% on a constant currency basis to $343.3 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com